PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34665696-7	2021	RESULTS: Baricitinib inhibited OSM-induced JAK signalling in RA synovial fibroblasts and effectively suppressed subsequent expression of the proinflammatory mediators IL-6, MCP-1 and IP-10.	baricitinib	9-20	C-C motif chemokine ligand 2	Homo sapiens	173-178	
34665696-9	2021	Although both TNFalpha and IL-1beta signal independently of the JAK/STAT pathway, in HSF, but not in RA FLS, baricitinib significantly inhibited TNFalpha- and IL-1beta-induced MCP-1 and IP-10 protein levels in a dose dependent manner.	baricitinib	109-120	C-C motif chemokine ligand 2	Homo sapiens	176-181	
34248953-11	2021	OSM-induced secretion of MCP-1 and IL-6 was inhibited by all JAKi with Peficitinib, Baricitinib and Upadacitinib showing the greatest effect.	baricitinib	84-95	C-C motif chemokine ligand 2	Homo sapiens	25-30	
33639176-7	2021	Baricitinib did modulate other soluble factors besides IFN-gamma, significantly decreasing the spike-specific-response mediated by IL-17, IL-1beta, IL-6, TNF-alpha, IL-4, IL-13, IL-1ra, IL-10, GM-CSF, FGF, IP-10, MCP-1, MIP-1beta (p <= 0.0156).	baricitinib	0-11	C-C motif chemokine ligand 2	Homo sapiens	213-218	
35164829-13	2022	Lastly, adalimumab, baricitinib, and tofacitinib treatment were able to attenuate the pembrolizumab-induced MCP-1 production (P = 0.0004, P = 0.033, and P = 0.025, respectively), while this was not seen with tocilizumab treatment (P = 0.75).	baricitinib	20-31	C-C motif chemokine ligand 2	Homo sapiens	108-113